Linked Life Data

16339391

Source:http://linkedlifedata.com/resource/pubmed/id/16339391

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16339391rdf:typepubmed:Citationlld:pubmed
pubmed-article:16339391lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C0025519lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C0030016lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C0597298lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C1135630lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C0076660lld:lifeskim
pubmed-article:16339391lifeskim:mentionsumls-concept:C1711207lld:lifeskim
pubmed-article:16339391pubmed:issue3lld:pubmed
pubmed-article:16339391pubmed:dateCreated2006-2-23lld:pubmed
pubmed-article:16339391pubmed:abstractTextTibolone [[7alpha,17alpha]-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one] is used to treat climacteric symptoms and prevent osteoporosis. It exerts tissue-selective effects via site-specific metabolism into 3alpha- and 3beta-hydroxymetabolites and a Delta4-isomer. Recombinant human cytosolic aldo-keto reductases 1C1 and 1C2 (AKR1C1 and AKR1C2) produce 3beta-hydroxytibolone, and the liver-specific AKR1C4 produces predominantly 3alpha-hydroxytibolone. These observations may account for the appearance of 3beta-hydroxytibolone in target tissues and 3alpha-hydroxytibolone in the circulation. Using liver autopsy samples (which express AKR1C1-AKR1C4), tibolone was reduced via 3alpha- and 3beta-hydroxysteroid dehydrogenase (HSD) activity. 3beta-Hydroxytibolone was exclusively formed in the cytosol and was inhibited by the AKR1C2-specific inhibitor 5beta-cholanic acid-3alpha, 7alpha-diol. The cytosolic formation of 3alpha-hydroxytibolone was inhibited by an AKR1C4-selective inhibitor, phenolphthalein. The ratio of these stereoisomers was 4:1 in favor of 3beta-hydroxytibolone. In HepG2 cell cytosol and intact cells (which do not express AKR1C4), tibolone was exclusively reduced to 3beta-hydroxytibolone and was blocked by the AKR1C1-AKR1C3 inhibitor flufenamic acid. In primary hepatocytes (which express AKR1C1-AKR1C4), time-dependent reduction of tibolone into 3beta- and 3alpha-hydroxytibolone was observed again in a 4:1 ratio. 3beta-HSD activity was inhibited by both 5beta-cholanic acid-3alpha,7alpha-diol and flufenamic acid, implicating a role for AKR1C2 and AKR1C1. By contrast, the formation of 3alpha-hydroxytibolone was exclusively inhibited by phenolphthalein implicating AKR1C4 in this reaction. 3beta- and 3alpha-Hydroxytibolone were rapidly metabolized into polar metabolites (>85%). The formation of minor amounts of tibolone was also observed followed by AKR1C-catalyzed epimerization. The low hepatic formation of 3alpha-hydroxytibolone suggests that AKR1C4 is not the primary source of this metabolite and instead it maybe formed by an intestinal or enterobacterial 3alpha-HSD.lld:pubmed
pubmed-article:16339391pubmed:languageenglld:pubmed
pubmed-article:16339391pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:citationSubsetIMlld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16339391pubmed:statusMEDLINElld:pubmed
pubmed-article:16339391pubmed:monthMarlld:pubmed
pubmed-article:16339391pubmed:issn0022-3565lld:pubmed
pubmed-article:16339391pubmed:authorpubmed-author:JinYiYlld:pubmed
pubmed-article:16339391pubmed:authorpubmed-author:PenningTrevor...lld:pubmed
pubmed-article:16339391pubmed:authorpubmed-author:KloosterboerH...lld:pubmed
pubmed-article:16339391pubmed:authorpubmed-author:Steckelbroeck...lld:pubmed
pubmed-article:16339391pubmed:authorpubmed-author:OyesanmiBusol...lld:pubmed
pubmed-article:16339391pubmed:authorpubmed-author:LeeSeon-HwaSHlld:pubmed
pubmed-article:16339391pubmed:issnTypePrintlld:pubmed
pubmed-article:16339391pubmed:volume316lld:pubmed
pubmed-article:16339391pubmed:ownerNLMlld:pubmed
pubmed-article:16339391pubmed:authorsCompleteYlld:pubmed
pubmed-article:16339391pubmed:pagination1300-9lld:pubmed
pubmed-article:16339391pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:meshHeadingpubmed-meshheading:16339391...lld:pubmed
pubmed-article:16339391pubmed:year2006lld:pubmed
pubmed-article:16339391pubmed:articleTitleTibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.lld:pubmed
pubmed-article:16339391pubmed:affiliationDepartment of Pharmacology, University of Pennsylvania School of Medicine, 130C John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6084, USA.lld:pubmed
pubmed-article:16339391pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16339391pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16339391lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16339391lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16339391lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16339391lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16339391lld:pubmed